Skip to content

Local Anaesthesia for Hernia surgery

Comparison between ropivacaine 0.5% and bupivacaine 0.5% in ilioinguinal-iliohypogastric nerve block for Inguinal Hernia Repair- A prospective randomised double blind study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/04/013131
Enrollment
70
Registered
2018-04-10
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- ASA Grade I, II, III Health Condition 2: K409- Unilateral inguinal hernia, without obstruction or gangrene

Interventions

Intervention1: Bupivacaine 0.5% with Lignocaine 2% or Ropivacaine 0.5% with Lignocaine 2%: Ilioinguinal iliohypogastric block given once before surgery and duration noted until patient complaints of p

Sponsors

Department of Anaesthesiology
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1)ASA Grade I, II and III 2)scheduled for uncomplicated inguinal hernia repair

Exclusion criteria

Exclusion criteria: 1)Patient refusal 2)Patients with known hypersensitivity to local anaesthetics 3)Patients with ASA grade IV or more 4)Paediatric age group ( 5)Morbid obesity (BMI >35kg/m2) 6)Complicated hernias such as irreducible, strangulated, incarcerated or recurrent hernia

Design outcomes

Primary

MeasureTime frame
To evaluate the efficacy of single-puncture technique of local anaesthesia for inguinal hernia repair.Timepoint: 1 year

Secondary

MeasureTime frame
To compare 0.5% bupivacaine with 0.5% ropivacaine, both in combination with 2% lignocaine-adrenaline regarding efficacy, safety and duration of post-operative analgesia in the patients undergoing unilateral inguinal hernia repair.Timepoint: 1 year

Countries

India

Contacts

Public ContactAditi Narang

Department of Anaesthesiology, RNT Medical College

dr_ikumari@hotmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026